BR0206492A - Composição farmacêutica para inibir a replicação de um vìrus dentro de células, uso de pelo menos um agonista receptor de adenosina a3, e, métodos para inibir a replicação de um vìrus em células - Google Patents
Composição farmacêutica para inibir a replicação de um vìrus dentro de células, uso de pelo menos um agonista receptor de adenosina a3, e, métodos para inibir a replicação de um vìrus em célulasInfo
- Publication number
- BR0206492A BR0206492A BR0206492-8A BR0206492A BR0206492A BR 0206492 A BR0206492 A BR 0206492A BR 0206492 A BR0206492 A BR 0206492A BR 0206492 A BR0206492 A BR 0206492A
- Authority
- BR
- Brazil
- Prior art keywords
- cells
- virus
- inhibiting replication
- receptor agonist
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Abstract
"COMPOSIçãO FARMACêUTICA PARA INIBIR A REPLICAçãO DE UM VìRUS DENTRO DE CéLULAS, USO DE PELO MENOS UM AGONISTA RECEPTOR DE ADENOSINA A3, E, MéTODOS PARA INIBIR A REPLICAçãO DE UM VìRUS EM CéLULAS". A presente invenção refere-se ao uso de um ingrediente ativo selecionado dentre o grupo consistindo de agonistas do sistema de receptor de adenosina para inibir a replicação viral em células. Particularmente, a invenção provê uma composição e método para inibir a replicação viral em células, o método compreendendo apresentar às células uma quantidade efetiva do ingrediente ativo. De acordo com uma forma de realização, o agonista de adenosina é um agonista de receptor A3 (A3RAg). A invenção é particularmente utilizável apesar de não limitada à inibição da replicação de vírus HIV em células humanas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26165901P | 2001-01-16 | 2001-01-16 | |
PCT/IL2002/000028 WO2002055085A2 (en) | 2001-01-16 | 2002-01-13 | Use of an adenosine a3 receptor agonist for inhibition of viral replication |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0206492A true BR0206492A (pt) | 2004-02-10 |
Family
ID=22994269
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0206492-8A BR0206492A (pt) | 2001-01-16 | 2002-01-13 | Composição farmacêutica para inibir a replicação de um vìrus dentro de células, uso de pelo menos um agonista receptor de adenosina a3, e, métodos para inibir a replicação de um vìrus em células |
Country Status (12)
Country | Link |
---|---|
US (1) | US7589075B2 (pt) |
EP (1) | EP1365776B1 (pt) |
JP (1) | JP4012070B2 (pt) |
CN (1) | CN1259056C (pt) |
AT (1) | ATE292973T1 (pt) |
AU (1) | AU2002219497B2 (pt) |
BR (1) | BR0206492A (pt) |
CA (1) | CA2434906C (pt) |
DE (1) | DE60203702T2 (pt) |
HK (1) | HK1064948A1 (pt) |
IL (1) | IL156704A0 (pt) |
WO (1) | WO2002055085A2 (pt) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020115635A1 (en) * | 2001-02-21 | 2002-08-22 | Pnina Fishman | Modulation of GSK-3beta activity and its different uses |
US7414036B2 (en) | 2002-01-25 | 2008-08-19 | Muscagen Limited | Compounds useful as A3 adenosine receptor agonists |
PE20060272A1 (es) | 2004-05-24 | 2006-05-22 | Glaxo Group Ltd | (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a |
EA011826B1 (ru) | 2004-05-26 | 2009-06-30 | Инотек Фармасьютикалз Корпорейшн | Пуриновые производные в качестве агонистов аденозиновых арецепторов и способы их применения |
EP1802316B1 (en) | 2004-09-20 | 2011-11-02 | Inotek Pharmaceuticals Corporation | Purine derivatives and methods of use thereof |
GT200500281A (es) | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
US20060194756A1 (en) * | 2004-11-22 | 2006-08-31 | Borea Pier A | Enhancing treatment of HIF-1 mediated disorders with adenosine A3 receptor agonists |
GB0500785D0 (en) | 2005-01-14 | 2005-02-23 | Novartis Ag | Organic compounds |
GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
JP5203214B2 (ja) | 2005-11-30 | 2013-06-05 | イノテック ファーマシューティカルズ コーポレイション | プリン化合物およびその使用方法 |
GB0607944D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
MY146645A (en) | 2006-04-21 | 2012-09-14 | Novartis Ag | Purine derivatives for use as adenosin a2a receptor agonists |
GB0607950D0 (en) | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
GB0607953D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
EP1889846A1 (en) | 2006-07-13 | 2008-02-20 | Novartis AG | Purine derivatives as A2a agonists |
EP1903044A1 (en) | 2006-09-14 | 2008-03-26 | Novartis AG | Adenosine Derivatives as A2A Receptor Agonists |
AU2007316715A1 (en) * | 2006-11-10 | 2008-05-15 | Novartis Ag | Cyclopentene diol monoacetate derivatives |
WO2008111082A1 (en) | 2007-03-14 | 2008-09-18 | Can-Fite Biopharma Ltd. | Process for the synthesis of ib-meca |
US20090088403A1 (en) * | 2007-05-07 | 2009-04-02 | Randy Blakely | A3 adenosine receptors as targets for the modulation of central serotonergic signaling |
WO2009050707A1 (en) * | 2007-10-15 | 2009-04-23 | Can-Fite Biopharma Ltd. | Method for inducing hepatocyte proliferation and uses thereof |
WO2011010306A1 (en) | 2009-07-21 | 2011-01-27 | Ramot At Tel-Aviv University Ltd. | A3 adenosine receptor ligands for modulation of pigmentation |
SI2523669T1 (sl) | 2010-01-11 | 2017-05-31 | Inotek Pharmaceuticals Corporation | Kombinacija, komplet in metoda za zmanjšanje intraokularnega tlaka |
WO2011119969A1 (en) | 2010-03-26 | 2011-09-29 | Inotek Pharmaceuticals Corporation | Method of reducing intraocular pressure in humans using n6 -cyclopentyladenosine (cpa), cpa derivatives or prodrugs thereof |
MX356509B (es) | 2011-12-22 | 2018-05-30 | Alios Biopharma Inc | Nucleósidos sustituidos, nucleótidos y análogos de los mismos. |
US20150018299A1 (en) * | 2012-01-23 | 2015-01-15 | Can-Fite Biopharma Ltd. | Treatment of liver conditions |
DK2807178T3 (en) | 2012-01-26 | 2017-09-04 | Inotek Pharmaceuticals Corp | Anhydrous polymorphs of (2R, 3S, 4R, 5R) -5- (6- (cyclopentylamino) -9H-purin-9-yl) -3,4-dihydroxytetrahydrofuran-2-yl) methyl nitrate and processes for their preparation |
US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
JP6140825B2 (ja) * | 2012-08-09 | 2017-05-31 | キャン−ファイト バイオファーマ リミテッドCan−Fite BioPharma Ltd. | 性機能不全の治療に使用するためのa3アデノシン受容体リガンド |
SG11201506882YA (en) | 2013-03-15 | 2015-09-29 | Inotek Pharmaceuticals Corp | Ophthalmic formulations |
IL242723B (en) | 2015-11-23 | 2019-12-31 | Can Fite Biopharma Ltd | A3 adenosine receptor ligand for the treatment of ectopic fat accumulation |
KR20220132042A (ko) | 2016-04-21 | 2022-09-29 | 아스트로사이트 파마슈티컬스, 인코포레이티드 | 신경계 및 심혈관계 병태 치료를 위한 화합물 및 방법 |
WO2019157317A1 (en) | 2018-02-09 | 2019-08-15 | Astrocyte Pharmaceuticals, Inc. | Compounds and methods for treating addiction and related disorders |
BR112021005290A2 (pt) | 2018-09-26 | 2021-06-22 | Astrocyte Pharmaceuticals, Inc. | compostos polimórficos e usos dos mesmos |
IL272078A (en) | 2020-01-16 | 2021-07-29 | Can Fite Biopharma Ltd | Cannabinoids for use in therapy |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5443836A (en) | 1993-03-15 | 1995-08-22 | Gensia, Inc. | Methods for protecting tissues and organs from ischemic damage |
US5688774A (en) * | 1993-07-13 | 1997-11-18 | The United States Of America As Represented By The Department Of Health And Human Services | A3 adenosine receptor agonists |
EP0708781B1 (en) * | 1993-07-13 | 2001-10-04 | THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services | A 3 adenosine receptor agonists |
JP2003517423A (ja) | 1997-07-29 | 2003-05-27 | メドコ リサーチ、インコーポレイテッド | アデノシンレセプターモジュレーターとしてのn6−置換アデノシン−5′−ウロナミド |
US6048865A (en) | 1997-07-29 | 2000-04-11 | Medco Research, Inc. | N6 -substituted-adenosine-5'-uronamides as adenosine receptor modulator |
WO1999020284A1 (en) | 1997-10-23 | 1999-04-29 | Trustees Of The University Of Pennsylvania | Methods for reducing ischemic injury of the heart via the sequential administration of monophosphoryl lipid a and adenosine receptor agents |
IL133680A0 (en) * | 1999-09-10 | 2001-04-30 | Can Fite Technologies Ltd | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist |
US8076303B2 (en) * | 2005-12-13 | 2011-12-13 | Spring Bank Pharmaceuticals, Inc. | Nucleotide and oligonucleotide prodrugs |
-
2002
- 2002-01-13 EP EP02729507A patent/EP1365776B1/en not_active Expired - Lifetime
- 2002-01-13 DE DE60203702T patent/DE60203702T2/de not_active Expired - Lifetime
- 2002-01-13 CA CA002434906A patent/CA2434906C/en not_active Expired - Lifetime
- 2002-01-13 CN CNB028037715A patent/CN1259056C/zh not_active Expired - Lifetime
- 2002-01-13 AT AT02729507T patent/ATE292973T1/de not_active IP Right Cessation
- 2002-01-13 IL IL15670402A patent/IL156704A0/xx active IP Right Grant
- 2002-01-13 US US10/466,263 patent/US7589075B2/en not_active Expired - Lifetime
- 2002-01-13 AU AU2002219497A patent/AU2002219497B2/en not_active Expired
- 2002-01-13 WO PCT/IL2002/000028 patent/WO2002055085A2/en active IP Right Grant
- 2002-01-13 JP JP2002555819A patent/JP4012070B2/ja not_active Expired - Lifetime
- 2002-01-13 BR BR0206492-8A patent/BR0206492A/pt not_active Application Discontinuation
-
2004
- 2004-10-11 HK HK04107798A patent/HK1064948A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
DE60203702T2 (de) | 2006-03-02 |
IL156704A0 (en) | 2004-01-04 |
CN1259056C (zh) | 2006-06-14 |
EP1365776B1 (en) | 2005-04-13 |
AU2002219497B2 (en) | 2004-08-26 |
JP4012070B2 (ja) | 2007-11-21 |
CA2434906C (en) | 2008-08-19 |
JP2004517864A (ja) | 2004-06-17 |
HK1064948A1 (en) | 2005-02-08 |
WO2002055085A3 (en) | 2002-12-19 |
US20040106572A1 (en) | 2004-06-03 |
CA2434906A1 (en) | 2002-07-18 |
DE60203702D1 (de) | 2005-05-19 |
US7589075B2 (en) | 2009-09-15 |
CN1489470A (zh) | 2004-04-14 |
WO2002055085A2 (en) | 2002-07-18 |
ATE292973T1 (de) | 2005-04-15 |
EP1365776A2 (en) | 2003-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0206492A (pt) | Composição farmacêutica para inibir a replicação de um vìrus dentro de células, uso de pelo menos um agonista receptor de adenosina a3, e, métodos para inibir a replicação de um vìrus em células | |
DK1283700T3 (da) | Farmaceutiske sustained release-præparater til parenteral administration af biologisk aktive hydrofile forbindelser | |
TR200002355T2 (tr) | 2-(Pürin-9-il)tetrahidrofüran-3,4-diol türevleri | |
YU78291A (sh) | 1,3-oksatiolanski nukleozidni analozi | |
BR0307524A (pt) | Composição farmacêutica para inibidores de protease viral de hepatite c | |
BR0010262A (pt) | Composição para formar um aerossol, processo de preparação e de aerossolização de uma composição, e, dispositivo gerador de aerossol | |
AU7788701A (en) | System and method for optimizing tissue barrier transfer of compounds | |
BR9911326A (pt) | Análogos macrocìclicos e métodos para seu uso e preparação | |
AR020442A1 (es) | Agonistas de 5ht2serotonergicos para el tratamiento de glaucoma | |
AR023044A1 (es) | Composicion farmaceutica soluble en agua en un complejo no ionico y uso del mismo | |
BRPI0518553A2 (pt) | composiÇço farmacÊutica estÁvel, mÉtodo para estabilizaÇço de pelo menos um ingrediente farmaceuticamente ativo e mÉtodo de uso de celulose microcristalina silicificada | |
EA200800162A1 (ru) | Новые фармацевтические композиции с замедленным высвобождением и способы их получения | |
ATE399847T1 (de) | Reinigungsmittel vom typ der multiplen emulsion | |
ES2147758T3 (es) | Preparacion sinergistica para la activacion de celulas destructoras naturales. | |
BRPI0309651B8 (pt) | método para prevenir ou reduzir a resistência a um pesticida de uma peste de substrato, composição de pesticida, uso dos mesmos, e, método para preparar uma composição de pesticida | |
BR0013009A (pt) | Uso de antagonistas de cgrp e de inibidores de liberação de cgrp para combate a jatos quentes menopáusicos | |
AU2003287491A8 (en) | Preformulation analysis and optimization | |
DE69836678D1 (de) | Chinolin- und chinazolinderivate als antagonisten des corticotropin freisetzenden faktors (crf) | |
WO2004085682A3 (de) | Caspase inhibitoren, insbesondere von caspase-3, zur behandlung von influenza | |
MXPA03004209A (es) | Composicion farmaceutica o cosmetica y uso de un inhbidor de proteina cinasa c con un inhibidor de metaloproteasas de la matriz para inhibir la migracion de celulas de langerhans. | |
BR0116152B1 (pt) | aditivo adequado para uso como emulsificador e solubilizador, uso de um aditivo, e, composição. | |
DK1558219T3 (da) | Farmaceutisk formulering af olanzapin | |
BR0010882A (pt) | Agonistas receptores de adenosina a1 oralmente ativos e processo para uso de tal composição | |
DE60008590D1 (de) | Zusammensetzungen von adenosin a1 agonisten und cox2-hemmern | |
RS50074B (sr) | Farmaceutski preparat koji sadrži paracetamol i drotaverin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B12B | Appeal against refusal [chapter 12.2 patent gazette] |